Immunodeficient BRGSF Mouse Model

Immunodeficient mouse

Compared to the traditional immunodeficient strains such as NOD-SCID and NSG, the BRGSF mouse represents the most adapted animal model to study and predict human immune responses in vivo.

Applications

This next generation mouse is a unique preclinical model to study:

  • Vaccine development
  • Efficacy and safety of chimeric antigen receptor (CAR) T cell therapy
  • Myeloid compartment development
  • Patient-derived xenograft (PDX)
  • Human CD34+ hematopoietic stem cell engraftment (see BRGSF-HIS)

BRGSF features

 

Or get supplemental information, a quote, and estimated timeframe for delivery of your BRGSF line.

  
  • Highly permissive to patient-derived xenografts (PDXs) and cell line engraftment by virtue of the SIRPαNOD expression
  • Suitable to assess the effects of radiation in vivo due to the absence of the SCID mutation on a BALB/c background
  • A powerful tool for complement-dependent cytotoxicity (CDC) studies because of the presence of a functional murine complement system

Immunodeficient BRGSF mouse

References for model validation

Model validation

Masse-Ranson G, Dusséaux M, Fiquet O, Darche S, Boussand M, Li Y, Lopez-Lastra S, Legrand N, Corcuff E, Toubert A, Centlivre M, Bruel T, Spits H, Schwartz O, Lévy Y, Strick-Marchand H, Di Santo JP.
Accelerated thymopoiesis and improved T-cell responses in HLA-A2/-DR2 transgenic BRGS-based human immune system mice.
Eur J Immunol. 2019 Mar 19.

Lopez-Lastra S, Masse-Ranson G, Fiquet O, Darche S, Serafini N, Li Y, Dusséaux M, Strick-Marchand H, Di Santo JP.
A functional DC cross talk promotes human ILC homeostasis in humanized mice.
Blood Adv. 2017 Apr 6.

Li Y, Mention JJ, Court N, Masse-Ranson G, Toubert A, Spits H, Legrand N, Corcuff E, Strick-Marchand H, Di Santo JP.
A novel Flt3-deficient HIS mouse model with selective enhancement of human DC development.
Eur J Immunol. 2016 May.

Legrand N1, Huntington ND, Nagasawa M, Bakker AQ, Schotte R, Strick-Marchand H, de Geus SJ, Pouw SM, Böhne M, Voordouw A, Weijer K, Di Santo JP, Spits H.
Functional CD47/signal regulatory protein alpha (SIRP(alpha)) interaction is required for optimal human T- and natural killer- (NK) cell homeostasis in vivo.
Proc Natl Acad Sci U S A. 2011 Aug 9.

 

Case studies

Vaccine development:
Fior J.
SupT1 Cell Infusion as a Possible Cell-Based Therapy for HIV: Results from a Pilot Study in Hu-PBMC BRGS Mice.
Vaccines (Basel). 2016 Apr 26.

CAR T-cell therapy:
Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, Duclert A, Sasu BJ, Duchateau P, Poirot L.
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies.

 

Patent

Di Santo JP and Mention JJ. Dentritic cell-boosted humanized immune system mice. PCT/US/2010/029800. WO 2010/115115 A1. Patent 2010.

Ready to be shipped to your lab

  • Cohorts available upon request
  • Studies can be carried out at your site or at your favorite CRO
  • VAF Elite/SOPF certification and worldwide delivery by professional breeders
  • Models provided with FTO on patent-protected technologies used for model generation